Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
about
Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines.The Biological Role of PI3K Pathway in Lung Cancer.Therapeutic biomarkers in lung neuroendocrine neoplasia.mTOR pathway: A current, up-to-date mini-review (Review).The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.Molecular insights: Suppression of EGFR and AKT activation by a small molecule in non-small cell lung cancer.Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.High miR-100 expression is associated with aggressive features and modulates TORC1 complex activation in lung carcinoids.
P2860
Q34911416-24C8C838-F843-49E6-B35F-C3969E5BCFFEQ38166599-1E830BC2-1F19-4470-8B30-88988D34EF89Q38253997-3861AB4A-A787-4D11-9C23-0FABABEAE608Q38264125-D8C209FC-B019-4755-AA40-E93C91C9089DQ38695102-CD64388A-BAD2-4719-B8D1-7674EB4C3CCCQ47130055-CC4F52BD-7FD6-4EAD-95DF-E873E97BDF9BQ47393972-38CCC646-8DA6-401A-A63E-BC5D5987962DQ51122180-7F2461AF-FF51-4CE0-9667-978951F2D844Q55262767-8F2EF8FA-C52E-49C8-9343-DBA7CF9874EE
P2860
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Synergistic effects of erlotin ...... tivated EGFR/AKT/mTOR pathway.
@en
Synergistic effects of erlotin ...... tivated EGFR/AKT/mTOR pathway.
@nl
type
label
Synergistic effects of erlotin ...... tivated EGFR/AKT/mTOR pathway.
@en
Synergistic effects of erlotin ...... tivated EGFR/AKT/mTOR pathway.
@nl
prefLabel
Synergistic effects of erlotin ...... tivated EGFR/AKT/mTOR pathway.
@en
Synergistic effects of erlotin ...... tivated EGFR/AKT/mTOR pathway.
@nl
P2093
P2860
P50
P356
P1433
P1476
Synergistic effects of erlotin ...... tivated EGFR/AKT/mTOR pathway.
@en
P2093
Andrea Haitel
Hubert Hayden
Józefa Węsierska-Gądek
Katharina Schmid
Martin Filipits
Oxana Komina
Wolfgang Sieghart
Zsuzsanna Bago-Horvath
P2860
P304
P356
10.1159/000337257
P577
2012-04-27T00:00:00Z